Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone

Peripheral mechanisms may be involved in opioid actions on the urinary bladder. This double-blind study investigated whether opioid inhibition of bladder function is reversed by methyinaltrexone, a peripheral opioid antagonist. Thirteen healthy male volunteers received an intravenous (i.v.) infusion of remifentanil, 0.15 mcg/kg/min, then a single i.v. dose of study medication (methyinaltrexone 0.3 mg/kg, naloxone 0.01 mg/kg, or saline). Urodynamics were measured with indwelling bladder and rectal catheters, and pupil size was assessed with infrared pupillometry. Remifentanil decreased cletrusor pressure in 21/25 sessions and caused complete urinary retention in 18/25. Voiding was possible in 7/7, 5/12, and 0/6 sessions after naloxone, methyinaltrexone, and saline, respectively (P = 0.0013). Remifentanil caused marked miosis that was reversed by naloxone, but not methyinaltrexone or placebo (P < 0.0001). The pupil data confirm that methylnaltrexone did not reverse central opioid effects. Reversal of urinary retention by methyinaltrexone indicates that peripheral mechanisms may play a role in opioid-induced bladder dysfunction.